Sale by Daniel Pichl of 858 shares of SpringWorks Therapeutics
| SWTX Stock | USD 54.14 0.11 0.20% |
Slightly above 52% of SpringWorks Therapeutics' investor base is interested to short. The analysis of the overall investor sentiment regarding SpringWorks Therapeutics suggests that many traders are impartial. SpringWorks Therapeutics' investing sentiment can be driven by a variety of factors including economic data, SpringWorks Therapeutics' earnings reports, geopolitical events, and overall market trends.
SpringWorks |
Filed transaction by Springworks Therapeutics officer. General open market or private sale of non-derivative or derivative security
Read at macroaxis.com
SpringWorks Therapeutics Fundamental Analysis
We analyze SpringWorks Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of SpringWorks Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of SpringWorks Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Operating Margin
Operating Margin Comparative Analysis
SpringWorks Therapeutics is currently under evaluation in operating margin category among its peers. Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
SpringWorks Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with SpringWorks Therapeutics stock to make a market-neutral strategy. Peer analysis of SpringWorks Therapeutics could also be used in its relative valuation, which is a method of valuing SpringWorks Therapeutics by comparing valuation metrics with similar companies.
Peers
SpringWorks Therapeutics Related Equities
| AMLX | Amylyx Pharmaceuticals | 4.58 | ||||
| PASG | Passage Bio | 1.92 | ||||
| RLAY | Relay Therapeutics | 1.90 | ||||
| RNA | Avidity Biosciences | 1.68 | ||||
| TERN | Terns Pharmaceuticals | 1.35 | ||||
| STOK | Stoke Therapeutics | 0.24 | ||||
| BPMC | Blueprint Medicines | 0.15 | ||||
| GLUE | Monte Rosa | 1.03 | ||||
| PLRX | Pliant Therapeutics | 1.58 | ||||
| KYMR | Kymera Therapeutics | 1.70 | ||||
| RVMD | Revolution Medicines | 2.03 | ||||
| APLS | Apellis Pharmaceuticals | 2.12 | ||||
| ARVN | Arvinas | 3.00 | ||||
| BDTX | Black Diamond | 6.45 | ||||
| SANA | Sana Biotechnology | 10.07 | ||||
| DAWN | Day One | 16.50 |
Additional Tools for SpringWorks Stock Analysis
When running SpringWorks Therapeutics' price analysis, check to measure SpringWorks Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SpringWorks Therapeutics is operating at the current time. Most of SpringWorks Therapeutics' value examination focuses on studying past and present price action to predict the probability of SpringWorks Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SpringWorks Therapeutics' price. Additionally, you may evaluate how the addition of SpringWorks Therapeutics to your portfolios can decrease your overall portfolio volatility.